Evidence map›Paper›PMID 41077614›Full record

ArticleMolecular neurodegeneration2025

Midbrain degeneration triggers astrocyte reactivity and tau pathology in experimental Alzheimer's Disease.

Livia La Barbera, Paraskevi Krashia, Gilda Loffredo, Emma Cauzzi, Maria Luisa De Paolis, Martina Montanari, Luana Saba, Elena Spoleti, Serena Ficchì, Claudio Zaccone and 11 more

Abstract read
In one paragraph

Article in Molecular neurodegeneration, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Livia La Barbera *Department of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Via Alvaro del Portillo, 21-00128, Rome, Italy.
Paraskevi Krashia *Department of Experimental Neurosciences, IRCCS Santa Lucia Foundation, Via del Fosso Di Fiorano, 64-00143, Rome, Italy.
Gilda Loffredo *Department of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Via Alvaro del Portillo, 21-00128, Rome, Italy.
Emma CauzziDepartment of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Via Alvaro del Portillo, 21-00128, Rome, Italy.
Maria Luisa De PaolisDepartment of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Via Alvaro del Portillo, 21-00128, Rome, Italy.
Martina MontanariDepartment of Experimental Neurosciences, IRCCS Santa Lucia Foundation, Via del Fosso Di Fiorano, 64-00143, Rome, Italy.
Luana SabaDepartment of Experimental Neurosciences, IRCCS Santa Lucia Foundation, Via del Fosso Di Fiorano, 64-00143, Rome, Italy.
Elena SpoletiDepartment of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Via Alvaro del Portillo, 21-00128, Rome, Italy.
Serena FicchìDepartment of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Via Alvaro del Portillo, 21-00128, Rome, Italy.
Claudio ZacconeDepartment of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Via Alvaro del Portillo, 21-00128, Rome, Italy.
Marco De BardiDepartment of Experimental Neurosciences, IRCCS Santa Lucia Foundation, Via del Fosso Di Fiorano, 64-00143, Rome, Italy.
Claudia PalazzoDepartment of Life Science and Public Health, Section of Histology and Embryology, Università Cattolica del Sacro Cuore, Largo Francesco Vito, 1-00168, Rome, Italy.
Ramona MarinoDepartment of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Via Alvaro del Portillo, 21-00128, Rome, Italy.
Emanuele Claudio LatagliataDepartment of Experimental Neurosciences, IRCCS Santa Lucia Foundation, Via del Fosso Di Fiorano, 64-00143, Rome, Italy.
Stefano Puglisi-AllegraIstituto Di Ricovero E Cura a Carattere Scientifico (IRCCS) Neuromed, Via Atinense, 18-86077, Pozzilli, Italy.
Giovanna BorsellinoDepartment of Experimental Neurosciences, IRCCS Santa Lucia Foundation, Via del Fosso Di Fiorano, 64-00143, Rome, Italy.
Flavio KellerDepartment of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Via Alvaro del Portillo, 21-00128, Rome, Italy.
Luisa Lo IaconoDepartment of Experimental Neurosciences, IRCCS Santa Lucia Foundation, Via del Fosso Di Fiorano, 64-00143, Rome, Italy.
Maria Teresa ViscomiDepartment of Life Science and Public Health, Section of Histology and Embryology, Università Cattolica del Sacro Cuore, Largo Francesco Vito, 1-00168, Rome, Italy.
Annalisa Nobili *Department of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Via Alvaro del Portillo, 21-00128, Rome, Italy.
Marcello D'Amelio *Department of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Via Alvaro del Portillo, 21-00128, Rome, Italy. m.damelio@unicampus.it.

Funding

Alzheimer's Association AARG-18-566270Alzheimer's Association AARG-21-851219Alzheimer's Association AARG-22-922961Ministero della Salute GR-2019-12370446Ministero della Salute RF-2018-12365527
6 · The paper itself

Abstract

backgroundSmaller midbrain volumes predict Alzheimer's Disease (AD) progression and faster conversion from Mild Cognitive Impairment (MCI) to dementia. Along with this, various midbrain-target areas are characterized by neuroinflammation since the MCI stage. The concomitance of neuroinflammation, Αβ and tau appears to be a strong predictor for conversion from MCI to dementia. Yet, how midbrain degeneration could cause disease progression, and what mechanisms are involved in triggering neuroinflammation in midbrain-target areas such as the hippocampus remain unexplored.

methodsUsing adult C57BL/6N mice we generated a new mouse model carrying lesions in three midbrain nuclei, the dopaminergic Ventral Tegmental Area (VTA) and Substantia Nigra pars compacta (SNpc) and the serotonergic Interpeduncular Nucleus (IPN), to evaluate the consequences of dopamine and serotonin deprivation in midbrain-target areas. We characterized this model by performing stereological cell counts, analysis of monoaminergic fibers, monoamine levels, electrophysiology and behavioral tests. We then assessed hippocampal neuroinflammation by analyzing glia cell count, changes in morphology, NLRP3 inflammasome activation and cytokine levels, and microglia transcriptional profiling. In a separate set of experiments, we induced experimental midbrain lesion in Tg2576 transgenic mice overexpressing the Swedish mutant amyloid precursor protein, to evaluate the effect of monoamine deprivation on the hippocampus in concomitance with amyloid-β (Aβ) accumulation. The lesion performed in Tg2576 mice, as opposed to that in C57BL/6N mice, provides valuable insights into how neuroinflammation is influenced by Aβ accumulation versus the exclusive impact of impaired monoaminergic signaling.

resultsThe concomitant depletion of dopaminergic and serotonergic inputs within the hippocampus of C57BL/6N mice provokes a pronounced activation of microglia via the NLRP3-inflammasome pathway, accompanied by increased IL-1β expression. Pharmacological intervention with either dopaminergic (L-DOPA or A68930) or serotonergic (fluoxetine) agents abrogates this neuroinflammatory response. In the Tg2576 transgenic mouse model of amyloid pathology, which exhibits progressive Aβ deposition, superimposed midbrain degeneration markedly amplifies AD-like neuropathology. This includes exacerbation of microglial reactivity, robust astrocyte response, precocious Aβ plaque burden, and induction of pathological tau hyperphosphorylation. Notably, administration of L-DOPA or fluoxetine significantly attenuates both the astrocyte reactivity and tau hyperphosphorylation in the lesioned Tg2576 cohort.

conclusionsThese results highlight the pivotal role of midbrain damage for the amplification of neuroinflammatory cascades and AD pathology. Moreover, they offer mechanistic insight into the faster progression to dementia in patients with midbrain deficits. By translating these findings into clinical practice, we can advance towards a precision medicine approach in disease management.

Indexed as

Alzheimer DiseaseAstrocytesMesencephalontau ProteinsAnimalsDisease Models, AnimalHippocampusMaleMiceMice, Inbred C57BLMice, Transgenictau ProteinsCognitive declineGene expression profilingMesolimbic systemMonoaminesNeurodegenerative diseaseSSRISynaptic plasticityTranscriptome

Identifiers

PMID41077614
PMCPMC12516900

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.